Your browser doesn't support javascript.
loading
Management of Hyperglycemia in COVID-19 and Post-COVID-19 Syndrome - Proposed Guidelines for India.
Nanditha, Arun; Raghavan, Arun; Misra, Anoop; Saboo, Banshi; Singh, Awadhesh Kumar; Joshi, Shashank R; Agarwal, Sanjay; Tandon, Nikhil; Tiwaskar, Mangesh; Aravind, Sosale R; Ramachandran, Ambady.
  • Nanditha A; Director, Consultant Diabetologist, India Diabetes Research Foundation and Dr. A. Ramachandran's Diabetes Hospitals, Chennai, Tamil Nadu.
  • Raghavan A; Director, Consultant Diabetologist, India Diabetes Research Foundation and Dr. A. Ramachandran's Diabetes Hospitals, Chennai, Tamil Nadu.
  • Misra A; Chairman, Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, Chairman, National Diabetes, Obesity and Cholesterol Foundation (N-DOC), President, Diabetes Foundation (India) (DFI), New Delhi.
  • Saboo B; Chief Diabetologist Chairman, Diabetes Care Hormone Clinic, Ahmedabad, Gujarat.
  • Singh AK; Senior Consultant Endocrinologist, G.D Hospital Diabetes Institute, Kolkata, West Bengal.
  • Joshi SR; Senior Consultant Endocrinologist, Lilavati Hospital and Medical Research Centre, Mumbai, Maharashtra.
  • Agarwal S; Director - Aegle Clinic for Diabetes Care, Head of Dept. Medicine Diabetes, Ruby Hall Clinic. Senior Consultant Diabetes Medicine, Jehangir Hospital, Pune, Maharashtra.
  • Tandon N; Professor Head, Department of Endocrinology Metabolism, All India Institute of Medical Sciences, New Delhi.
  • Tiwaskar M; Consultant Physician Diabetologist, Shilpa Medical Research Centre, Mumbai, Maharashtra.
  • Aravind SR; Director, Diacon Hospital, Bangalore, Karnataka; 10President, India Diabetes Research Foundation, Chairman, Dr. A. Ramachandran's Diabetes Hospitals, Chennai, Tamil Nadu.
  • Ramachandran A; President, India Diabetes Research Foundation, Chairman, Dr. A. Ramachandran's Diabetes Hospitals, Chennai, Tamil Nadu.
J Assoc Physicians India ; 69(9): 11-12, 2021 Sep.
Article en En | MEDLINE | ID: mdl-34585892
ABSTRACT
SARS-CoV-2 virus spread rapidly all over the globe in 2020 and the second wave has taken our nation, India by storm. The pandemic has posed unique challenges in people with metabolic disorders, including diabetes, hypertension, obesity, pulmonary, cardiovascular, kidney and non-alcoholic fatty liver disease. Uncontrolled diabetes, in conjunction with endocrine, inflammatory and metabolic effects of the infection itself has made management of hyperglycemia in COVID-19 infection particularly challenging. Furthermore, the post-COVID-19 syndrome has also emerged as a sequela in COVID-19 survivors, increasing the risk of death, complications and adding further burden on the health care system. With more than a year of experience, we have gained substantial insight; and now provide practical recommendations on the management of hyperglycemia in COVID-19 as well as post COVID-19 syndrome.
Asunto(s)
Search on Google
Banco de datos: MEDLINE Asunto principal: COVID-19 / Hiperglucemia Tipo de estudio: Etiology_studies / Guideline Límite: Humans País como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article
Search on Google
Banco de datos: MEDLINE Asunto principal: COVID-19 / Hiperglucemia Tipo de estudio: Etiology_studies / Guideline Límite: Humans País como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article